Long-Term Results of Atacicept in IgAN Will Be Presented at ASN Kidney Week

Vera Therapeutics announced that long-term results of the ORIGIN phase 2b study of atacicept to treat IgA nephropathy (IgAN) will be the subject of a late-breaking oral presentation and two posters at the upcoming American Society of Nephrology (ASN) Kidney Week in San Diego, California.

Richard Lafayette, MD, FACP, professor of medicine (nephrology) and director of the Stanford Glomerular Disease Center at Stanford University Medical Center, will present the posters “ORIGIN 3: A Global Randomized, Controlled, Phase 3 Study of Atacicept in IgAN” and “ORIGIN Extend: A Long-Term Extension Study of Atacicept in IgAN,” on October 25.

Jonathan Barratt, MD, PhD, FRCP, the Mayer Professor of Renal Medicine at the University of Leicester, will lead the oral presentation, “Long-term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgAN” on October 26.

Atacicept is the leading product candidate of Vera Therapeutics, a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. The drug is a fusion protein, self-administered as a subcutaneous injection once weekly, that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL).

Atacicept received US Food and Drug Administration Breakthrough Therapy Designation for the treatment of IgAN based on an assessment of data from the phase 2b ORIGIN clinical trial. The trial met its primary and key secondary endpoints, with statistically significant and clinically meaningful proteinuria reductions and stabilization of eGFR versus placebo through 36 weeks. The safety profile during the randomized period was comparable between atacicept and placebo. Through 72 weeks, atacicept demonstrated further reductions in Gd-IgA1, hematuria, and proteinuria, as well as stabilization of eGFR, reflecting a profile consistent with that of the general population.

In 2025, Vera plans to launch the PIONEER study to evaluate the efficacy and safety of atacicept for expanded IgAN populations and additional autoimmune glomerular diseases characterized by the presence of antibodies to glomerular antigens, including primary membranous nephropathy, focal segmental glomerulosclerosis, and minimal change disease.